Oral IDH1 Inhibitor Ivosidenib Holds Rare Liver Cancer at Bay for 35 Months in Case Report
A case report documents 35 months of oral ivosidenib therapy with partial remission and no adverse events in a man ...
A case report documents 35 months of oral ivosidenib therapy with partial remission and no adverse events in a man ...
A phase 3 trial shows sacituzumab tirumotecan significantly lowers the risk of cancer progression and death in women with recurrent ...
Mandimycin M16 neutralized 11 priority fungal pathogens in vitro and outperformed amphotericin B in mouse models of systemic Candida infection ...
A narrative review concludes that severe obesity can complicate ICU drug dosing and supports individualized regimens based on pharmacokinetic variability ...
An in vitro study found that a repurposed darifenacin-betamethasone formulation reduced the fitted streptomycin IC50 by 2.2-fold in a resistant ...
A focused review finds that antibody–drug conjugates directly kill breast-cancer cells, while evidence that they remodel human tumor immunity remains ...
A cross-sectional study of 76 adults with Crohn’s disease at a Baghdad hospital found that higher ustekinumab trough concentrations were ...
A laboratory study found that ivermectin weakened cisplatin-associated cytotoxicity, apoptosis and S-phase arrest in HN9 oral cancer cells.
A sweeping review in Food Chemistry: X maps how AI, IoT, blockchain and green analytical chemistry could transform veterinary drug ...
A year of pharmacovigilance reports from Ho Chi Minh City shows that of 253 confirmed adverse reactions to anticancer drugs, ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine